Filing Scope and Business Context
The provided filing is an unaudited Form 10-Q for Olivia Ventures, Inc., not Compass Therapeutics, Inc. It covers the quarter and six months ended September 30, 2019, with comparative periods ended September 30, 2018. The company was incorporated in March 2018 as a blank-check and shell company seeking to acquire or merge with an operating business. It has conducted no active operating business and has generated no revenue.
Financial Performance and Condition
| Metric | Three Months Ended September 30, 2019 | Six Months Ended September 30, 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative expense | $7,151 | $17,469 |
| Interest expense | $1,252 | $2,396 |
| Net loss | $8,403 | $19,865 |
| Loss per common share | $0.00 | $0.00 |
- At September 30, 2019, cash and total assets were $882, compared with $4,866 at March 31, 2019.
- Current liabilities were $91,336, up from $75,455 at March 31, 2019. Stockholders’ deficit was $90,454.
- The company had $85,610 principal outstanding under a stockholder note and $5,726 of accrued interest, with the total amount due reported as $91,336.
- Six-month operating cash outflow was $17,469, compared with $12,679 in the prior-year period.
- Six-month financing cash inflow was $13,485, consisting of proceeds from the stockholder note. Net cash decreased by $3,984, versus a $2,446 increase in the prior-year period.
- No material off-balance-sheet arrangements were reported. No income tax expense was recorded because the company maintains a full valuation allowance against its deferred tax asset.
Material Changes Versus the Prior Comparable Period
- Six-month net loss increased to $19,865 from $17,030, a deterioration of $2,835.
- Six-month general and administrative expenses increased to $17,469 from $15,679, while interest expense increased to $2,396 from $1,351.
- Operating cash usage increased to $17,469 from $12,679.
- Financing proceeds declined to $13,485 from $15,125, and ending cash fell to $882 from $2,446 at September 30, 2018.
- The company continued to report no revenue and no operating business activity.
Outlook, Risks, Contingencies, and Unusual Items
- Management plans to continue seeking a suitable business combination; as of the filing date, no definitive agreement or specific discussions with a candidate had been entered into or reported.
- Management stated that recurring losses, approximately $91,000 of losses from inception, negative working capital of approximately $90,000, and limited cash raise substantial doubt about the company’s ability to continue as a going concern for the twelve months following issuance of the financial statements.
- Management expects to fund operations through additional borrowings under the existing stockholder note, equity financing connected with a reverse merger, or related-party advances. There is no assurance that funding will be available.
- The stockholder note bears interest at 6% annually and becomes subject to an 18% rate beginning five days after a defined event of default.
- Any eventual target could be financially unstable, early-stage, or operating in a high-risk industry. A single business combination could result in substantial dilution and limited diversification.
- The company is a shell company and blank-check company, has no listed securities, and reported 5,000,000 common shares outstanding as of November 12, 2019.
- No material pending legal proceedings, unregistered securities sales, senior-security defaults, or other reportable items were disclosed.
Investor Verification Priorities
- Verify the issuer identity: the supplied filing is for Olivia Ventures, Inc., while the request identifies Compass Therapeutics, Inc.
- Confirm the $91,336 stockholder-note balance, including the $85,610 principal and $5,726 accrued interest, and review the note’s default provisions.
- Assess the going-concern uncertainty and the company’s ability to obtain additional related-party or equity financing.
- Determine whether any business-combination discussions or agreements arose after the September 30, 2019 reporting date.
- Review the company’s shell-company status, ownership structure, potential dilution, and any limitations on future use of approximately $91,000 of net operating loss carryforwards.